CALC trial: Aprepitant for the treatment of cough in lung cancer
ISRCTN | ISRCTN16200035 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN16200035 |
Secondary identifying numbers | 13989 |
- Submission date
- 26/03/2013
- Registration date
- 26/03/2013
- Last edited
- 24/09/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Contact information
Dr Amelie Harle
Scientific
Scientific
Department of Medical Oncology
550 Wilmslow Road
Manchester
M20 4BX
United Kingdom
Amelie.Harle@christie.nhs.uk |
Study information
Study design | Randomised single-arm placebo-controlled crossover study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised cross over trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
Scientific title | A single-arm double-blind placebo-controlled cross-over trial of Aprepitant for the treatment of cough in lung cancer: CALC trial |
Study acronym | CALC |
Study objectives | A single-arm placebo controlled crossover study of Aprepitant for the treatment of cough in lung cancer. Aprepitant is an effective antitussive for patients with lung cancer. |
Ethics approval(s) | NRES Committee North West Liverpool East, 22/03/2013, ref: 13/NW/0084 |
Health condition(s) or problem(s) studied | Topic: National Cancer Research Network; Subtopic: Lung Cancer; Disease: Lung (small cell), Lung (non-small cell) |
Intervention | Patients will receive 3 days treatment with aprepitant/placebo at standard doses: 125mg D1, 80mg D2 and 80mg D3 followed by 3 days washout period and 3 further days of aprepitant/placebo at standard doses. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Aprepitant |
Primary outcome measure | Daytime ambulatory cough monitoring; Timepoint(s): Baseline, D3 and D9 |
Secondary outcome measures | 1. Biomarker Analysis; Timepoint(s): Day 3 and Day 9 2. Cough Severity Visual Analogue Scale score; Timepoint(s): Baseline, Day 3 and Day 9 3. Manchester Cough in Lung Cancer Scale score; Timepoint(s): Baseline, Day 3 and Day 9 |
Overall study start date | 01/04/2013 |
Completion date | 31/03/2014 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | Planned Sample Size: 20; UK Sample Size: 20 |
Total final enrolment | 20 |
Key inclusion criteria | 1. Patients willing and able to give consent for participation in the trial 2. Male or female aged 18 years or above 3. WHO PS 02 4. Diagnosed with lung cancer 5. Able and willing to participate in and comply with the trial schedule 6. Persistent cough >= 4 weeks 7. Not on anticancer therapy 8. No anticancer therapy planned to commence for the duration of the trial participation |
Key exclusion criteria | 1. Received anticancer therapy within 4 weeks of trial entry 2. Receiving Aprepitant therapy 3. Presence of a RTI within last 4 weeks 4. Previous adverse event to Aprepitant 5. Presence of constipation grade 2 or above (CTCAE v4) 6. Scheduled elective surgery or other procedures requiring sedation or general anaesthesia during trial period 7. Potentially fertile women of childbearing age 8. Currently participating in another research trial involving an investigational product 9. Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial or affect the patients ability to participate in the trial |
Date of first enrolment | 01/04/2013 |
Date of final enrolment | 31/03/2014 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Christie Hospital NHS Foundation Trust
Manchester
M20 4BX
United Kingdom
M20 4BX
United Kingdom
Sponsor information
Christie Hospital NHS Foundation Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
550 Wilmslow Road
Manchester
M20 4BX
England
United Kingdom
Website | http://www.christie.nhs.uk/ |
---|---|
https://ror.org/03v9efr22 |
Funders
Funder type
Government
National Institute for Health Research (NIHR) (UK)
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
North West Lung Centre Charity (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Plain English results | No | Yes | |||
Results article | results | 10/10/2015 | Yes | No | |
Results article | results | 15/03/2021 | 24/09/2020 | Yes | No |
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
24/09/2020: The following changes have been made:
1. Publication reference added.
2. The total final enrolment number has been added from the reference.
19/03/2019: Link to results (plain English) added.
07/02/2017: Publication reference added.